In an initial screen for tumor type sensitivity to triple PIM/PI3K/mTOR inhibition by IBL‐302, 707 cell lines derived from 47 different tumor types were tested by the Genomics of Drug Sensitivity in Cancer (GDSC) screening program (Yang et al, 2013). This evidence concerns the gene PIM1 and cancer.